Logo image of ALCOX.PA

NICOX SA (ALCOX.PA) Stock Price, Quote, News and Overview

EPA:ALCOX - Euronext Paris - Matif - FR0013018124 - Common Stock - Currency: EUR

0.2255  +0.01 (+2.5%)

ALCOX.PA Quote, Performance and Key Statistics

NICOX SA

EPA:ALCOX (6/17/2025, 7:00:00 PM)

0.2255

+0.01 (+2.5%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.34
52 Week Low0.14
Market Cap15.65M
Shares69.38M
Float62.88M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-16 2025-07-16
IPO11-02 1999-11-02


ALCOX.PA short term performance overview.The bars show the price performance of ALCOX.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

ALCOX.PA long term performance overview.The bars show the price performance of ALCOX.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40

The current stock price of ALCOX.PA is 0.2255 EUR. In the past month the price decreased by -0.22%. In the past year, price increased by 9.73%.

NICOX SA / ALCOX Daily stock chart

ALCOX.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1ABBV.MI ABBVIE INC 18.69 293.65B
4AB.DE ABBVIE INC 18.09 283.68B
AMG.DE AMGEN INC 14.23 137.38B
GIS.DE GILEAD SCIENCES INC 14.11 117.44B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 99.51B
1REGN.MI REGENERON PHARMACEUTICALS 11.98 49.56B
ARGX.BR ARGENX SE 102.34 28.87B
22UA.DE BIONTECH SE-ADR N/A 21.80B
IDP.DE BIOGEN INC 8.15 16.35B
1EXEL.MI EXELIXIS INC 18.93 9.81B
1MRNA.MI MODERNA INC N/A 8.71B
0QF.DE MODERNA INC N/A 8.67B

About ALCOX.PA

Company Profile

ALCOX logo image Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 5 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Company Info

NICOX SA

Sundesk Sophia Antipolis, Batiment C, Emerald Square, rue Evariste Galois

BIOT PACA FR

Employees: 5

ALCOX Company Website

ALCOX Investor Relations

Phone: 33497245300

NICOX SA / ALCOX.PA FAQ

What is the stock price of NICOX SA today?

The current stock price of ALCOX.PA is 0.2255 EUR. The price increased by 2.5% in the last trading session.


What is the ticker symbol for NICOX SA stock?

The exchange symbol of NICOX SA is ALCOX and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALCOX.PA stock listed?

ALCOX.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for NICOX SA stock?

9 analysts have analysed ALCOX.PA and the average price target is 1.02 EUR. This implies a price increase of 352.33% is expected in the next year compared to the current price of 0.2255. Check the NICOX SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NICOX SA worth?

NICOX SA (ALCOX.PA) has a market capitalization of 15.65M EUR. This makes ALCOX.PA a Nano Cap stock.


How many employees does NICOX SA have?

NICOX SA (ALCOX.PA) currently has 5 employees.


What are the support and resistance levels for NICOX SA (ALCOX.PA) stock?

NICOX SA (ALCOX.PA) has a support level at 0.22 and a resistance level at 0.23. Check the full technical report for a detailed analysis of ALCOX.PA support and resistance levels.


Is NICOX SA (ALCOX.PA) expected to grow?

The Revenue of NICOX SA (ALCOX.PA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALCOX.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NICOX SA (ALCOX.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NICOX SA (ALCOX.PA) stock pay dividends?

ALCOX.PA does not pay a dividend.


When does NICOX SA (ALCOX.PA) report earnings?

NICOX SA (ALCOX.PA) will report earnings on 2025-07-16.


What is the Price/Earnings (PE) ratio of NICOX SA (ALCOX.PA)?

NICOX SA (ALCOX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).


ALCOX.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALCOX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALCOX.PA. ALCOX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALCOX.PA Financial Highlights

Over the last trailing twelve months ALCOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 23.81% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -92.83%
ROE -653.37%
Debt/Equity 4.4
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)23.81%
Revenue 1Y (TTM)13.86%

ALCOX.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to ALCOX.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 16% and a revenue growth -100% for ALCOX.PA


Ownership
Inst Owners6.33%
Ins Owners0.13%
Short Float %N/A
Short RatioN/A
Analysts
Analysts84.44
Price Target1.02 (352.33%)
EPS Next Y16%
Revenue Next Year-100%